Ngomhla wama-31 kuJulayi, ngo-2025, i-ImmuneOnco Biopharmaceuticals yabhengeza idatha yokuqala yokhuseleko kunye nokusebenza kakuhle evela kwiSigaba sesi-2 sophando oluvulekileyo, oluneziko ezininzi lwe-IMM2510 kunye ne-chemotherapy kwizigulana ezikwicala elingaphambili ezine-advanced non-small cell lung cancer (NSCLC) eyenziwe eTshayina.
Ukususela nge-1 kaJulayi 2025, izigulana ezingama-33 zanikwa idosi ye-10 mg/kg, kunye nezigulana ezingama-21 ezazivavanywe ubuncinci ithumba elinye (ukusebenza kakuhle kuyavavanywa). Iimpendulo ezingaphelelanga zabonwa kwi-62% yezigulana ezazivavanywa ukusebenza kakuhle, kuquka iimpendulo ezingaphelelanga kwi-80% (8/10) yezigulana ezine-NSCLC ene-squamous kunye ne-46% (5/11) yezigulana ezine-NSCLC engeyiyo i-squamous. Uninzi lwezigulana ezazivavanywa ukusebenza kakuhle zazivavanywe ithumba elinye kuphela xa idatha yayinqunyulwa. I-ImmuneOnco ilindele ukubonisa idatha yokhuseleko kunye nokusebenza kakuhle kwisilingo sokudibanisa i-chemotherapy se-IMM2510 kwi-NSCLC yangaphambili kwingqungquthela yezonyango yexesha elizayo.
Iprofayili yokhuseleko ye-IMM2510 ixhasa uphuhliso oluqhubekayo lwezonyango, kungekho bungozi bokunciphisa umthamo obubonwe kwizigulana ezingama-33 ezivavanywayo kukhuseleko. Kwezi zigulana, bekungekho ziganeko zimbi ezinxulumene nonyango (TRAE) ezikhokelela ekunciphiseni umthamo okanye ekufeni, kwaye bekukho i-TRAE enye kuphela ekhokelela ekuyekeni ukusebenzisa amayeza. Ezona TRAE zixhaphakileyo zeBanga lesi-3+ zazizi-hematologic, kunye neziphumo ezingaqhelekanga zeklinikhi. Iziganeko ezibi zihlala zinxulunyaniswa nokuthintelwa kwe-VEGF (umz., uxinzelelo lwegazi, i-proteinuria, i-hemoptysis) kunye neziganeko ezibi ezinxulumene nokuzikhusela komzimba bezingaqhelekanga kwaye ngokubanzi ziphantsi, kwaye iimpendulo ezinxulumene nokufakwa emzimbeni phantse zonke beziphantsi.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Ixesha lokuthumela: Agasti-05-2025